David A. Siegel Avadel Pharmaceuticals PLC Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $159,424 - $309,824	18,800 Added 17.79%	124,500 $2.05 Million
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $80,766 - $125,369	12,600 Added 13.53%	105,700 $968,000
Q4 2022 Feb 14, 2023	SELL	$5.02 - $10.0 $13,553 - $27,000	-2,700 Reduced 2.82%	93,100 $666,000
Q3 2022 Nov 14, 2022	BUY	$2.57 - $7.31 $170,391 - $484,653	66,300 Added 224.75%	95,800 $480,000
Q2 2022 Aug 15, 2022	BUY	$1.07 - $6.95 $31,565 - $205,025	29,500 New	29,500 $72,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.